- Academic background
- Health Sciences
- Host campus
- Master's, Honours
- Pathology (Dunedin)
- Dr Sunali Mehta
There is a continuous need to identify patients with aggressive disease and therapies they are most likely to benefit from.
p53 is known as the “guardian of the genome” and is a commonly mutated gene in cancer. Frequently occurring p53 mutations have been studied in great details, but have failed to gain clinical utility. With access to mutation data from approximately 10,000 cancers, it is becoming evident that 75% of p53 mutations are uncommon and it remains to be understood how they affect cancer.
The student project will be using cell culture, gene editing techniques (CRISPR-Cas9) and RNA-sequencing to understand how these uncommon p53 mutations contribute to cancer progression.
Overall this study will provide insights into the contribution of uncommon p53 mutations to cancer and identify clinical management strategies for these cancers.
Similar research opportunities
- A phoenix from the ashes: Do dying cancer cells induce drug-tolerance in lung cancer?
- A role for untranslated p53 mRNA in drug resistance
- Characterisation of YB-1 interactions with the cytoskeleton using live cell imaging
- Characteristion of YB-1 interactions with the cytoskeleton using live cell imaging
- Defining mechanisms controlling aberrant Fn14 regulation in cancer progression